Sample Newsalerts
-
AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B
Shots: CI Comments/ Implications: Commencing this partnership between AbbVie and TeneoOne,...
-
Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for CLL
in RegulatoryShots: The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvaro v...
-
BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours
Shots: The agreement involves assessing safety, efficacy and tolerability of BeiGene’...
-
AbbVie Reports FDA’s Hold on All Clinical Trials Evaluating Venclexta/Venclyxto (venetoclax) for Multiple Myeloma
in RegulatoryShots: The partial clinical hold follows P-III BELLINI trial (M14-031) study results asses...
-
Roche to Acquire Spark Therapeutics for $4.3B
in AcquisitionShots: CI Comments/ Implications: Roche’s interest in acquiring Spark was fueled lar...
-
Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B
in AcquisitionShots: BMS acquires Celgene, in all stock transaction for $74B. Celgene to receive $50/sha...